Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03966742
Recruitment Status : Completed
First Posted : May 29, 2019
Last Update Posted : March 25, 2022
Information provided by (Responsible Party):
Eldad Elnekave, MD, Rabin Medical Center

Brief Summary:
In this study Drug-eluting microbeads (DEB) loaded with Doxorubicin will be delivered into the target Desmoid Fibromatoses (DF) tissue via selective arterial embolization by angiographic technique. The objective of the study is to demonstrate the safety and efficacy of this treatment.

Condition or disease Intervention/treatment Phase
Desmoid Desmoid Fibromatosis of Skin Desmoid Neoplasm of Chest Wall Desmoid Tumor Caused by Somatic Mutation Aggressive Fibromatoses Fibromatosis Desmoid Desmoid Fibromatosis Procedure: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis Phase 2

Detailed Description:

Desmoid Fibromatoses (DF) are locally aggressive lesions associated with substantial morbidity and potentially mortality, due to invasion of adjacent neurovascular structures and vital organs. They have no potential for metastasis. Histologically, they are characterised by mature fibroblasts within a matrix of abundant fibrous stroma. While 5-15% of cases are seen in patients with Familial Adenomatous Polyposis (FAP) syndrome, the vast majority arise sporadically.

The etiology of Desmoids remains poorly understood and the therapeutic approaches in their management remain very diverse. For resectable lesions, surgery is recommended but reported cure rates range broadly from 12-80%. Systemic treatments range from non-steroidal anti-inflammatories and anti-estrogenic therapy to targeted tyrosine kinase inhibitors and cytotoxic chemotherapy, most commonly methotrexate, vinblastine and doxorubicin.

Doxorubicin is an anthracycline with demonstrated efficacy in treating desmoids at systemic IV doses of 50- 75mg/m2 over 3-4 week cycles. Extended use is limited by dose - dependent cardiotoxicity which can be seen in up to 36% of patients receiving doses in excess of 550mg/m2. Delayed cardiotoxicity is particularly common and less predictable among pediatric cancer survivors.

Selective trans-arterial chemo-embolization (TACE) is a method to achieve high tissue drug concentration with minimal systemic toxicity. Historically, this has been achieved by mixing doxorubicin with embolic agents such as lipiodol or gelatin sponge in the treatment of hepatocellular carcinoma (HCC).

Drug-eluting microbeads (DEB) ionically loaded with doxorubicin have shown sustained release in TACE target tissues with substantially lower serum drug concentrations when compared to lipiodol TACE.

The present study utilizes DEB's loaded with Doxorubicin delivered into the target DF tissue via selective arterial embolization by angiographic technique. This study follows a successful feasibility study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: All patients
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
Actual Study Start Date : October 11, 2018
Actual Primary Completion Date : December 18, 2020
Actual Study Completion Date : December 18, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment
Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.
Procedure: Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis

Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.

Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe.

Primary Outcome Measures :
  1. Objective response rate of tumor size. [ Time Frame: At baseline ; 6-10 weeks after each treatment ]
    Response to treatment. Measured by change in tumor size according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria.

  2. Objective response rate of tumor biological activity. [ Time Frame: At baseline ; 6-10 weeks after each treatment ]
    Response to treatment. Tumor biological activity measured by change in MRI T2 signal intensity.

  3. Patient reported outcomes. [ Time Frame: At baseline ; 6-10 weeks after each treatment ]

    Change in clinical symptoms measured by standard clinical patient questionnaires - EORTC QLQ-C30. (Quality of Life Questionnaire).

    All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high level of functioning, a high score for the global health status / QoL represents a high QoL. Similarly, a high score for a symptom scale represents a high level of symptomatology.

Secondary Outcome Measures :
  1. Adverse event profile (safety) [ Time Frame: At baseline ; 6-10 weeks ]
    Treatment safety measured by standard patient questionnaires and clinical evaluation using CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.

Other Outcome Measures:
  1. Pharmacokinetics of Doxorubicin [ Time Frame: 5 minutes, 30 minutes, 1 hour, 12 hours, 24 hours after treatment procedure ]
    Measurements of blood Doxorubicin concentration (mg/ml) over time, after treatment.

  2. Exploratory biomarkers [ Time Frame: At baseline ; 6-10 weeks ]
    Immunohistochemistry assay assessing the staining pattern (marked as negative to mildly or strongly positive) for: beta-catenin, keratin, SMA (smooth muscle actin). Ki-67 staining will be scored by percentage.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 3-80 years.
  2. Histologically confirmed diagnosis of Desmoids Fibromatosis.
  3. After at least one systemic treatment line. Standard first line systemic treatment may include: Methotrexate, Vinblastine, Doxorubicin, Liposomal Doxorubicin (Doxil), NSAIDS or hormonal treatment. If first line treatment is renounced, this treatment decision must be documented. Considering the trend of avoiding surgical treatment, the documentation must include that the treatment decision is not associated to the resectability of the tumor.
  4. Karnofsky performance status (PS)>50% for patients older than 16 years or Lansky PS >50% for patients under 16 years.
  5. At least one measurable lesion, with a long diameter of at least 30mm, with an anatomical location accessible for endovascular treatment.
  6. T2 signal increase on MRI.
  7. No evidence of prior treatment toxicity, adequate washout period after prior treatment:

    • 14 days after myelosuppressive chemotherapy treatment.
    • 7 days after GCSF (Granulocyte colony-stimulating factor), 14 days after Neulastim.
    • 7 days after targeted/biologic treatment.
  8. Female patients of childbearing potential must be willing to use an adequate method of contraception (hormonal, barrier or abstinence) for the treatment period and up to 90 days after the treatment completion.
  9. Willing and able to provide written informed consent for the trial.

Exclusion Criteria:

  1. Participation in another interventional study.
  2. Congestive heart failure, characterised by LVEF (Left Ventricular Ejection Fraction) < 50% or Shortening fracture < 27%.
  3. Previous treatment with anthracycline of a accumulative dose of more than 360 mg/m2.
  4. History of allergic reaction attributed to Doxil or doxorubicin treatment.
  5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit compliance with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03966742

Layout table for location information
Rabin Medical Center
Petach-Tikva, Israel
Sponsors and Collaborators
Rabin Medical Center
Layout table for additonal information
Responsible Party: Eldad Elnekave, MD, Director, Clinic Interventional Oncology, Rabin Medical Center Identifier: NCT03966742    
Other Study ID Numbers: RMC-0485-17
First Posted: May 29, 2019    Key Record Dates
Last Update Posted: March 25, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibromatosis, Aggressive
Behavioral Symptoms
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type